A Phase 3 Multicenter Randomized Open-Label Trial of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma

Go Back to All Clinical Trials

A Phase 3 Multicenter Randomized Open-Label Trial of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma

Brief description of study

The purpose of this trial is to evaluate whether the addition of epcoritamab to R-CHOP can improve outcomes versus R-CHOP alone in first-line therapy of high-risk DLBCL patients.

Clinical Study Identifier: s20-02024

ClinicalTrials.gov Identifier: NCT05578976

Principal Investigator: Catherine M Diefenbach.

Other Investigators: Maxim Kreditor, Marc Justin Braunstein, Bonnie Kiner-Strachan, Kenneth B Hymes, Michael L. Grossbard, John Leslie Vaughn, Ellaine R Yap, Shella Saint Fleur-Lominy, David Kaminetzky, Tibor Moskovits, Bruce G Raphael, Thaleshravi Prashad.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies